FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2064787268> ?p ?o ?g. }

• W2064787268 endingPage "S84" @default.
• W2064787268 startingPage "S78" @default.
• W2064787268 abstract "After excisional treatment, cervical intraepithelial neoplasia grade 2 or worse (CIN 2+) can recur. It is not clear how many negative posttreatment Pap or cotest results are needed to ensure adequate safety against CIN 2+ before returning to extended retesting intervals.We observed 5-year risks of CIN 2+ for 3 follow-up management strategies after treatment (Pap-alone, human papillomavirus [HPV]-alone, and HPV/Pap cotesting) for 3,273 women aged 25 years and older who were treated for CIN 2, CIN 3, or adenocarcinoma in situ (AIS) between 2003 and 2010 at Kaiser Permanente Northern California.Five-year risks of recurrent CIN 2+ after treatment varied both by antecedent screening test result and the histology of the treated lesion. The risk ranged from 5% for CIN 2 preceded by HPV-positive/atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion to 16% for CIN 3/AIS preceded by atypical glandular cells (AGC)/atypical squamous cells cannot rule out high-grade squamous intraepithelial lesion (ASC-H)/high-grade squamous intraepithelial lesion or worse (HSIL+) (p < .0001). However, after posttreatment negative tests, risks were lowered and similar regardless of antecedent screening test and histology of treated disease. The 5-year recurrent CIN 2+ risk after a negative posttreatment cotest (2.4%) was lower than that following a negative HPV test (3.7%, p = .3) or negative Pap result (4.2%, p = .1). Two negative posttreatment tests of each kind conferred slightly lower 5-year CIN 2+ risk than one (2 negative Pap tests vs. 1, 2.7% vs 4.2%, p = .2; 2 negative HPV tests vs. 1, 2.7% vs 3.7%, p = .7; 2 negative cotests vs. 1, 1.5% vs 2.4%, p = .8). The 5-year CIN 2+ risk after 2 negative cotests of 1.5% (95% confidence interval = 0.3%-7.2%) approached the 0.68% risk after a negative Pap test during routine screening.Women with antecedent AGC/ASC-H/HSIL+ Pap results or those treated for CIN 3/AIS had a substantial risk of developing CIN 2+ posttreatment. On the basis of the principle of equal management of equal risks, after negative test results posttreatment, no subgroup of women achieved risk sufficiently low to return to 5-year routine screening. However, negative cotests after treatment provided more reassurance against recurrent CIN 2+ than either negative Pap tests or HPV tests alone." @default.
• W2064787268 created "2016-06-24" @default.
• W2064787268 creator A5004506157 @default.
• W2064787268 creator A5009110617 @default.
• W2064787268 creator A5031936639 @default.
• W2064787268 creator A5042212667 @default.
• W2064787268 creator A5048359390 @default.
• W2064787268 creator A5054472987 @default.
• W2064787268 creator A5059813707 @default.
• W2064787268 creator A5059951020 @default.
• W2064787268 creator A5075288631 @default.
• W2064787268 creator A5091770473 @default.
• W2064787268 date "2013-04-01" @default.
• W2064787268 modified "2023-09-24" @default.
• W2064787268 title "Five-Year Risk of Recurrence After Treatment of CIN 2, CIN 3, or AIS" @default.
• W2064787268 cites W1972686404 @default.
• W2064787268 cites W1988590161 @default.
• W2064787268 cites W1992515073 @default.
• W2064787268 cites W2003130595 @default.
• W2064787268 cites W2025983816 @default.
• W2064787268 cites W2033684167 @default.
• W2064787268 cites W2040233988 @default.
• W2064787268 cites W2042683710 @default.
• W2064787268 cites W2044482604 @default.
• W2064787268 cites W2056868509 @default.
• W2064787268 cites W2058886042 @default.
• W2064787268 cites W2114791928 @default.
• W2064787268 cites W2121680483 @default.
• W2064787268 cites W2129656799 @default.
• W2064787268 cites W2133765716 @default.
• W2064787268 cites W2140820558 @default.
• W2064787268 cites W2146197530 @default.
• W2064787268 cites W2159111104 @default.
• W2064787268 cites W2166632132 @default.
• W2064787268 cites W2169411821 @default.
• W2064787268 cites W2170789578 @default.
• W2064787268 cites W2330443144 @default.
• W2064787268 cites W2395982254 @default.
• W2064787268 doi "https://doi.org/10.1097/lgt.0b013e31828543c5" @default.
• W2064787268 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3616418" @default.
• W2064787268 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23519309" @default.
• W2064787268 hasPublicationYear "2013" @default.
• W2064787268 type Work @default.
• W2064787268 sameAs 2064787268 @default.
• W2064787268 citedByCount "71" @default.
• W2064787268 countsByYear W20647872682013 @default.
• W2064787268 countsByYear W20647872682014 @default.
• W2064787268 countsByYear W20647872682015 @default.
• W2064787268 countsByYear W20647872682016 @default.
• W2064787268 countsByYear W20647872682017 @default.
• W2064787268 countsByYear W20647872682018 @default.
• W2064787268 countsByYear W20647872682019 @default.
• W2064787268 countsByYear W20647872682020 @default.
• W2064787268 countsByYear W20647872682021 @default.
• W2064787268 countsByYear W20647872682022 @default.
• W2064787268 countsByYear W20647872682023 @default.
• W2064787268 crossrefType "journal-article" @default.
• W2064787268 hasAuthorship W2064787268A5004506157 @default.
• W2064787268 hasAuthorship W2064787268A5009110617 @default.
• W2064787268 hasAuthorship W2064787268A5031936639 @default.
• W2064787268 hasAuthorship W2064787268A5042212667 @default.
• W2064787268 hasAuthorship W2064787268A5048359390 @default.
• W2064787268 hasAuthorship W2064787268A5054472987 @default.
• W2064787268 hasAuthorship W2064787268A5059813707 @default.
• W2064787268 hasAuthorship W2064787268A5059951020 @default.
• W2064787268 hasAuthorship W2064787268A5075288631 @default.
• W2064787268 hasAuthorship W2064787268A5091770473 @default.
• W2064787268 hasBestOaLocation W20647872682 @default.
• W2064787268 hasConcept C121608353 @default.
• W2064787268 hasConcept C126322002 @default.
• W2064787268 hasConcept C142724271 @default.
• W2064787268 hasConcept C2775924586 @default.
• W2064787268 hasConcept C2776117191 @default.
• W2064787268 hasConcept C2776235491 @default.
• W2064787268 hasConcept C2777343196 @default.
• W2064787268 hasConcept C2778220009 @default.
• W2064787268 hasConcept C2779534503 @default.
• W2064787268 hasConcept C2781156865 @default.
• W2064787268 hasConcept C29456083 @default.
• W2064787268 hasConcept C2994532551 @default.
• W2064787268 hasConcept C57742111 @default.
• W2064787268 hasConcept C71924100 @default.
• W2064787268 hasConcept C90924648 @default.
• W2064787268 hasConceptScore W2064787268C121608353 @default.
• W2064787268 hasConceptScore W2064787268C126322002 @default.
• W2064787268 hasConceptScore W2064787268C142724271 @default.
• W2064787268 hasConceptScore W2064787268C2775924586 @default.
• W2064787268 hasConceptScore W2064787268C2776117191 @default.
• W2064787268 hasConceptScore W2064787268C2776235491 @default.
• W2064787268 hasConceptScore W2064787268C2777343196 @default.
• W2064787268 hasConceptScore W2064787268C2778220009 @default.
• W2064787268 hasConceptScore W2064787268C2779534503 @default.
• W2064787268 hasConceptScore W2064787268C2781156865 @default.
• W2064787268 hasConceptScore W2064787268C29456083 @default.
• W2064787268 hasConceptScore W2064787268C2994532551 @default.
• W2064787268 hasConceptScore W2064787268C57742111 @default.
• W2064787268 hasConceptScore W2064787268C71924100 @default.
• W2064787268 hasConceptScore W2064787268C90924648 @default.

• next